Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid
Christina Muzny A C , Arti Barnes B and Leandro Mena B
+ Author Affiliations
- Author Affiliations
A Division of Infectious Diseases, University of Alabama at Birmingham, ZRB 242, 1530 3rd Avenue South, Birmingham, AL 35294, USA.
B Division of Infectious Diseases, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
C Corresponding author. Email: cmuzny@uab.edu
Sexual Health 9(4) 389-391 https://doi.org/10.1071/SH11114
Submitted: 11 August 2011 Accepted: 28 November 2011 Published: 20 January 2012
Abstract
This report describes a patient with symptomatic Trichomonas vaginalis infection who was unable to tolerate nitroimidazole drugs because of severe hypersensitivity, for which desensitisation was not possible. Use of intravaginal clotrimazole, intravaginal paromomycin, intravaginal furazolidone, povidone–iodine douches, and oral nitazoxanide were unsuccessful in eradicating the patient’s T. vaginalis infection. A 2-month course of intravaginal topical boric acid subsequently achieved a complete symptomatic cure and the patient remained T. vaginalis wet prep- and culture-negative 60 days after treatment.
Additional keywords: clotrimazole, furazolidone, hypersensitivity, nitazoxanide, povidone–iodine.
References
[1] Forna F, Gülmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003; CD000218| 1:STN:280:DC%2BD3s3nslenuw%3D%3D&md5=a4b3566f3c7fda0825e94b2097599e30CAS | 12804391PubMed |
[2] Soper D. Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol 2004; 190 281–90.
| Trichomoniasis: under control or undercontrolled?Crossref | GoogleScholarGoogle Scholar | 14749674PubMed |
[3] Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep 2010; 59 1–110.
[4] Pearlman MD, Yashar C, Ernst S, Solomon W. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reactions to metronidazole. Am J Obstet Gynecol 1996; 174 934–6.
| An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reactions to metronidazole.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK283gtlGmtQ%3D%3D&md5=76489490975c497e123c946a1aec2790CAS | 8633672PubMed |
[5] Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88 279–80.
| Metronidazole hypersensitivity and oral desensitization.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3MzkvFCnsQ%3D%3D&md5=856c339510ce41e5d76d752638a91b3aCAS | 1880329PubMed |
[6] Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008; 198 370.e1–7.
| Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity.Crossref | GoogleScholarGoogle Scholar |
[7] Cedillo-Rivera R, Chavez B, Gonzalez-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis, and Trichomonas vaginalis trophozoites. J Eukaryot Microbiol 2002; 49 201–8.
| In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis, and Trichomonas vaginalis trophozoites.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD38XmtVGitrw%3D&md5=3851394d1a8976d19faae9c88e714cccCAS | 12120985PubMed |
[8] Wright JM, Dunn LA, Kazimierczuk Z, Burgess AG, Krauer KG, Upcroft P, et al Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2′-deoxyadenosine. Parasitol Res 2010; 107 847–53.
| Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2′-deoxyadenosine.Crossref | GoogleScholarGoogle Scholar | 20532912PubMed |
[9] Blaha C, Duchene M, Aspock H, Walochnik J. In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis. J Antimicrob Chemother 2006; 57 273–8.
| In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XovVGiuw%3D%3D&md5=e44cf3d1a43942ff522835d86e4c787eCAS | 16344287PubMed |
[10] Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother 1996; 40 1121–5.
| 1:CAS:528:DyaK28XislClsbs%3D&md5=0650d57f1a5f531d870d28aa81a0c2deCAS | 8723451PubMed |
[11] Dan M, Sobel J. Failure of nitazoxanide to cure trichomonas in three women. Sex Transm Dis 2007; 34 813–4.
| 17551415PubMed |
[12] Goldman LM, Upcroft JA, Workowski KA, Rapkin A. Treatment of metronidazole-resistant Trichomonas vaginalis. Sex Health 2009; 6 345–7.
| Treatment of metronidazole-resistant Trichomonas vaginalis.Crossref | GoogleScholarGoogle Scholar | 19917205PubMed |
[13] Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998; 26 986–8.
| Difficult-to-treat trichomoniasis: results with paromomycin cream.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1c3isFKktg%3D%3D&md5=885f1a223bd2c2647e00e810ebd2a5e9CAS | 9564487PubMed |
[14] Wong CA, Wilson D, Chew TA. Povidone–iodine in the treatment of metronidazole-resistant Trichomonas vaginalis. Aust N Z J Obstet Gynaecol 1990; 30 169–71.
| Povidone–iodine in the treatment of metronidazole-resistant Trichomonas vaginalis.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3cznvF2rsw%3D%3D&md5=f0873019e01960c564a58df7240c596dCAS | 2400364PubMed |
[15] Livengood CH, Lossick JG. Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal nonoxynol-9. Obstet Gynecol 1991; 78 954–6.
| 1656351PubMed |
[16] Aggarwal A, Shier RM. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. J Obstet Gynaecol Can 2008; 30 55–8.
| 18198069PubMed |
[17] Bedi RS. Metronidazole-induced asthma. Indian J Chest Dis Allied Sci 1991; 33 213–5.
| 1:STN:280:DyaK383pvFertA%3D%3D&md5=0c93dd4473e0bb53f26b2a7475941f3fCAS | 1818846PubMed |
[18] Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88 279–80.
| Metronidazole hypersensitivity and oral desensitization.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3MzkvFCnsQ%3D%3D&md5=856c339510ce41e5d76d752638a91b3aCAS | 1880329PubMed |
[19] Añíbarro B, Fontela JL. Immediate rhinoconjunctivitis induced by metamizole and metronidazole. Ann Allergy Asthma Immunol 1997; 78 345–6.
| Immediate rhinoconjunctivitis induced by metamizole and metronidazole.Crossref | GoogleScholarGoogle Scholar | 9109700PubMed |
[20] Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28 325–6.
| 1:STN:280:DyaK2c3ltV2rtA%3D%3D&md5=8b5f0ed0fb7c74b1a7cc75b200662263CAS | 8193418PubMed |
[21] Asensio Sánchez T, Dávila I, Moreno E, Laffond E, Macías E, Ruiz A, et al Anaphylaxis due to metronidazole with positive skin prick test. J Investig Allergol Clin Immunol 2008; 18 138–9.
| 18447147PubMed |
[22] Porapakkham S. Metronidazole treatment of vaginal trichomoniasis. II. Oral vs. vaginal therapy. Obstet Gynecol 1967; 29 213–6.
| 1:STN:280:DyaF2s%2FptFemtQ%3D%3D&md5=107cd8a26a5269bd4083776ba65bac83CAS | 6018168PubMed |
[23] Krieger JN, Anagonou S. Trichomonas vaginalis and trichomoniasis. In Holmes KK, Sparling PF, Mardh PA, et al., eds. Sexually transmitted diseases. 3rd edn. New York: McGraw-Hill; 1999. pp. 587–604.
[24] Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11 300–17.
| 1:CAS:528:DyaK1cXislers74%3D&md5=204753e3b597eefbeca5093a2b6695c2CAS | 9564565PubMed |
[25] Garber GE, Lemchuk-Favel LT, Bowie WR. Isolation of a cell-detaching factor of Trichomonas vaginalis. J Clin Microbiol 1989; 27 1548–53.
| 1:CAS:528:DyaL1MXkvFemtbY%3D&md5=344f60fdfc128d07fcec0343ea0f4adcCAS | 2788661PubMed |
[26] Pindak FF, Gardner WA, Mora de Pindak M. Growth and cytopathogenicity of Trichomonas vaginalis in tissue cultures. J Clin Microbiol 1986; 23 672–8.
| 1:STN:280:DyaL287ps1Kguw%3D%3D&md5=bfb6b227ffef04b1b90ec7208ce1a52bCAS | 3486191PubMed |
